Immunotherapy in Hematological Malignancies: Recent Advances and Open Questions
Essam A. Tawfik, Norah A Aldrak, Shahad H. Albrahim, Dunia A. Alzahrani, Haya A. Alfassam, Samar M Alkoblan, Abdulaziz Almalik, Kok‐Siong Chen, Rana Abou-Khalil, Khalid Shah, Nada Zaidan
Abstract
Over recent years, tremendous advances in immunotherapy approaches have been observed, generating significant clinical progress. Cancer immunotherapy has been shown, in different types of blood cancers, to improve the overall survival of patients. Immunotherapy treatment of hematopoietic malignancies is a newly growing field that has been accelerating over the past years. Several US FDA approved drugs and cell-based therapies are being exploited in the late stage of clinical trials. This review attempt to highlight and discuss the numerous innovative immunotherapy approaches of hematopoietic malignancy ranging from nonmyeloablative transplantation, T-cell immunotherapy, natural killer cells and immune agonist to monoclonal antibodies and vaccination. In addition, a brief discussion on the future advances and accomplishments required to counterpart the current immunotherapeutic approaches for hematopoietic malignancies were also highlighted.